Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment
Clinical trial NCT04882345 · UNKNOWN
Trial details
- NCT number
- NCT04882345
- Sponsor
- Shanghai Chest Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-15
- Primary completion
- 2024-01-15
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.